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Abstract
Background: The leading causes of death in patients who died with a functioning allograft are 
cardiovascular diseases, which account for almost 40 percent of all deaths in this population.
Patients and Methods: We studied prospectively basic data, immunosuppressive therapy, drug 
levels, serum electrolytes (Na, K, Mg), HbA1C, renal functions (serum creatinine, eGFR, and urea), 
and urinalysis. Then oral glucose tolerance test was performed as well, and HOMA index was 
calculated.
Result: The ratio of patients changed at Minute 120 of the test: there were 22 (37%) patients in the 
normal group, 26 (43%) patients in the IFG/IGT group, and 12 (20%) patients in the NODAT group. 
Regarding basic data, hemodialysis (p=0.662) and body mass index (p=0.854) did not influence the 
development of diabetes mellitus significantly. Development of NODAT was significantly different 
between the Tac and CsA groups (p=0.027). Tac increased fasting drug level had a significant effect 
in the development of NODAT (p=0.036). The results of laboratory tests showed no significant 
difference in serum electrolytes. HbA1C (p=0.009) and HOMA index (p=0.09) were significantly 
different. Renal function parameters, such as serum creatinine (p=0.001) and eGFR (p=0.0001), 
were also significantly different.
Conclusion: In our clinical study, the risk of NODAT related to Tacrolimus is dose dependent and 
high trough levels enhance this risk, in particular during the new onset diabetes mellitus period.
Keywords: Kidney transplantation; Calcineurin inhibitors; NODAT; Diabetes mellitus
Introduction
New-Onset Diabetes After Transplantation (NODAT) is a serious and frequent metabolic 
complication after renal transplantation [1,2]. This entity has been well defined since the publication 
of the International Consensus Guidelines in 2003. The factors contributing to the risk of NODAT 
and the strategies related to modifiable factors, with emphasis on practical issues are reviewed in 
this paper. Many studies show that the Calcineurin Inhibitors (CNI), within them Tacrolimus (Tac) 
is the leading causes of the development of NODAT, and high Tac drug level contributes to the 
development of NODAT. Recognizing these factors may help clinicians to evaluate appropriate 
prevention strategies prospectively to minimize the risk of NODAT. Over the past 50 years, the 
concept of NODAT has evolved in terms of name and definition. Before 2003, de novo diabetes 
that developed after transplantation was described in various terms, most frequently as “new onset 
diabetes after transplantation” and suffered from a lack of consensus regarding its definition [3]. 
The most commonly used clinical definition was the requirement of insulin for a minimum period 
post-transplantation (often 30 days). This issue was addressed by the development of the 2003 
Consensus Guidelines, developed by the American Diabetes Association (ADA) and the World 
Health Organization (WHO) [4]. A diagnosis of NODAT carries a threat to the renal allograft, as 
well as the same short-and long-term implications of type 2 diabetes seen in the general population. 
NODAT usually occurs early after transplantation and is usually diagnosed according to the 
general population guidelines. According to these guidelines, diabetes is present if the fasting blood 
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glucose level is ≥ 7 mmol/L or if the blood glucose level measured 
2-h following the oral administration of 75 g glucose, the Oral 
Glucose Tolerance Test (OGTT) is ≥ 11.1 mmol/L. Impaired Fasting 
Glucose (IFG) is defined as a fasting blood glucose level between 5.6 
mmol/L and 6.9 mmol/L, whereas the Normal Value (N) for fasting 
blood glucose is <5.6 mmol/L or Impaired Glucose Tolerance (IGT) 
(2-h values in the OGTT) is between 7.8 mmol/L and 11.0 mmol/L. 
OGTT was performed in each patient. Patients with blood glucose 
level ≥ 11.0 mmol/L were selected for the NODAT group. The general 
principle behind standardized NODAT incidence reporting is that 
the diagnostic criteria should reflect what is used in the general 
population. Hopefully, these developments will allow for more 
consistent reporting of NODAT in the future, leading in turn to more 
precise estimates of incidence rates.
The aim of our study was to compare the risk factors and incidence 
of NODAT. We aimed to compare the effects of the Calcineurin 
inhibitors such as Tacrolimus (Tac) and Cylosporin-A (CsA) on 
NODAT. The further aim of the study was to decide whether the Tac 
drug level was suppressed by the development of NODAT, and what 
effects it had on the allograft function.
Material and Methods
Our prospective study was performed in the Department of 
Surgery, University of Szeged, Hungary. Patients who had cadaver 
kidney transplantation within at least one year, were above the age 
of 18, had no diabetes mellitus in the past medical history, have not 
received steroid burst therapy, and had no cardiac disease in the past 
medical history were enrolled in the study. A total of 60 patients were 
involved in our study.
Basic data (age, gender, and BMI), time spent in hemodialysis, 
and the applied Immunosuppressive (IS) therapy-CNI such as Tac 
and Cyclosporine-A (CsA) were analyzed. Laboratory tests were 
performed including serum electrolytes (Na, K, Mg), drug level, 
HbA1C, renal functions (serum creatinine, estimated glomerular 
filtration rate (eGFR), and urea) and urinalysis (total protein and 
glucose secretion). Then OGTT was performed as well, during which 
glucose and insulin levels were measured 0 and 120 mins after the 
administration of 75 g oral glucose, and then insulin resistance was 
calculated by using the Homeostatic Model Assessment (HOMA) 
index (fasting glucose* fasting glucose/22.5). Based on the value, the 
risk of Insulin Resistance (IR) can be determined, if the value is above 
2, the patient is susceptible to have diabetes mellitus, and in case of a 
value above 4, the patient has IR.
Our study was approved by the Regional Human Biomedical 
Research Ethics Committee of the Albert Szent-Györgyi Clinical 
Center, University of Szeged (Reg No: 18/2017-SZTE). Each patient 
was provided comprehensive information regarding the study.
Statistical Methods
Continuous data were expressed as mean ± standard deviation; 
categorical data were expressed as number of cases and percentages. 
Univariate comparisons were performed by Welch’s ANOVA or 
Chi-square test for continuous or categorical variables, respectively. 
The relationship between drug level and the development of diabetes 
mellitus was evaluated with ROC analysis; AUC ROC and 95% 
confidence interval for AUC were calculated. A p-value p<0.05 
was regarded statistically significant. Statistical software IBM SPSS 
statistics version 24 (64bit) was used.
Results
In our study, there were 30 patients in the normal group, 23 
patients in the IFG group, and 7 patients in the NODAT at Minute 
0 of OGTT. The ratio of patients changed at Minute 120 of the test: 
there were 22 (37%) patients in the normal group, 26 (43%) patients 
in the IFG/IGT group, and 12 (20%) patients in the NODAT group 
(Figure 1). After the transplantation, every patient was administered 
steroid therapy. In 50 cases, basic IS therapy included Tac, 9 patients 
received CsA based therapy, and 1 patient received CNI-free IS 
therapy. 10 (16%) patients from the NODAT group received Tac 
based therapy, and 2 (3%) patients received CsA based IS, significant 
difference was found between these two groups (p=0.027). ROC 
analysis of patients receiving Tac showed that increased fasting drug 
level had a significant effect in the development of diabetes mellitus 
(AUC=0.684, p=0.036, 95% CI: 0.534, 0.834) (Figure 2, Table 1).
The risk factors of diabetes were examined to determine which 
factors influence the development of diabetes mellitus significantly. 
Regarding basic data, gender and age did not influence the 
development of diabetes mellitus significantly, although patients with 
NODAT spent more time in HD; the difference was not statistically 
significant (p=0.662). In our study, BMI (26.55 ± 3.84 vs. 28.58 ± 
5.26; p=0.854) did not play a significant role in the development of 
NODAT (Table 2).
The results of laboratory tests showed no significant difference 
in serum electrolytes, such as Na (p=0.761), K (p=0.648), and Mg 
(p=0.306). Renal function parameters, such as serum creatinine 
(p=0.001) and eGFR (p=0.0001) were significantly different, while 
urea (p=0.176) level did not differ significantly between groups with 
different carbohydrate metabolism. The urine total protein level was 
Figure 1: Results of the OGTT.
N: Normal; IFG: Impaired Fasting Glucose; IGT: Impaired Glucose Tolerance; 
NODAT: New Onset Diabetes After Transplantation.
Figure 2: ROC curve for drug level (with diagonal reference line).
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significantly different in the groups (p=0.0001). HbA1C (p=0.009) 
and HOMA index were considered to be the indicator of insulin 
resistance (p=0.09), and C-peptide levels (p=0.20) were significantly 
different as well. Significant difference was found in the total urine 
protein level between the different glucose metabolic groups (Table 
3). The analysis of the glucose content of the urine showed that there 
was no glucose in the urine except for 4 cases of patients having 
NODAT, and 3 (+) glucose was found in the urine in 2 cases. Patients 
having normal carbohydrate metabolism had no glucose in the urine 
(p=0.0001).
Calcineurin inhibitors
The initial daily dose of Tac (0.20 mg/kg in 2 portions) was 
adjusted to target blood trough levels of 10-15 ng/mL at Week 6, and 
5-10 ng/mL thereafter. The initial CsA dose was 8-10 ng/kg daily in 
2 portions with target blood levels at two hours post-dose of 1,300-
1,600 ng/mL at Month 1; 900-1300 ng/mL at Months 2 and 3; 750-950 
ng/mL at Months 4-6; and 700 ng/mL thereafter.
The reported rates of NODAT in patients treated with Calcineurin 
inhibitors vary widely [1,3,5-9] for many of the same reasons that 
were stated earlier. However, some patient populations appear to be 
at increased risk for NODAT, depending on the type of CNI used. 
Although African Americans and Hispanics are more likely to develop 
new-onset DM regardless of the immunosuppressant used, they are 
particularly susceptible to DM after treatment with Tac [10,11].
Mechanism of calcineurin inhibitor-induced NODAT
The exact mechanism of NODAT induced by Tac and CsA is 
not known. In vitro and in vivo studies suggest that CsA affects the 
synthesis and secretion of insulin through reversible toxicity to β-cells 
[12,13]. In addition, insulin release may be independently affected by 
CsA, because CsA also inhibits the release of insulin in response to a 
glucose challenge in vitro and in the perfused pancreas [9,14]. CsA also 
affects peripheral glucose tolerance, presumably through a mechanism 
of insulin resistance. In the rat model, glucose intolerance precedes 
a drop in insulin secretion, suggesting peripheral mechanisms that 
reduce insulin secretion by β-cells [15]. Tac appears to have a similar 
mechanism of action to CsA, affecting β-cells and peripheral insulin 
sensitivity [3,11]. However, in human pancreatic β-cells, Tac has been 
shown to produce a greater alteration in the normal insulin secretion 
pattern than CsA [16]. There is also evidence that both Tac and CsA 
may act directly on the transcriptional regulation of insulin gene 
expression in β-cells [17-19].
Discussion
After kidney transplantation, the incidence of NODAT was 
 N IFG/IGT NODAT p value
Tac (number of patients) 18 22 10  
drug level 6.29 ± 1.27 8.46 ± 5.13 8.48 ± 2.24 0.016
CsA (number of patients) 3 4 2  
drug level 76.00 ± 36.7 34.82 ± 58.11 26.65 ± 33.02 0.511
Table 1: Calcineurin inhibitors fasting drugs levels.
Tac: Tacrolimus; CsA: Cyclosporine A; N: Normal; IFG: Impaired Fasting Glucose; IGT: Impaired Glucose Tolerance; NODAT: New Onset Diabetes After Transplantation
N 
(n=22)
Mean ± SD
IFG/IGT
(n=26)
Mean ± SD
NODAT 
(n=12)
Mean ± SD
p value
age (years) 48.86 ± 5.83 48.38 ± 6.85 48.83 ± 7.16 0.616
gender (women/men) 7/15 10/16 5/7 0.824
BMI (kg/m2) 26.55 ± 3.84 26.43 ± 3.41 28.58 ± 5.26 0.854
hemodialysis (months) 22.91 ± 20.30 29.38 ± 36.16 20.58 ± 25.26 0.662
Table 2: Basic data of the different glucose metabolism groups.
N: Normal; IFG: Impaired Fasting Glucose; IGT: Impaired Glucose Tolerance; NODAT: New Onset Diabetes After Transplantation; BMI: Body Mass Index; SD: 
Standard Deviation
 
N 
(n=22) 
 mean ± SD
IFG/IGT 
 (n=26)  
mean ± SD
NODAT 
 (n=12) 
 mean ± SD
p value
sodium 142.59 ± 2.64 142.26 ± 3.05 142.91 ± 91 0.761
potassium 4.51 ± 0.67 4.68 ± 0.65 4.56 ± 0.69 0.648
magnesium 0.76 ± 0.09 0.72 ± 0.10 0.77 ± 0.08 0.306
se. creatinine (µmol/L) 131.45 ± 18.25 120.88 ± 32.69 247.33 ± 91.35 0.001
urea (µmol/L) 10.31 ± 4.46 9.69 ± 6.71 14.02 ± 9.65 0.176
eGFR(mL/min/1.73m2) 50.90 ±11.27 58.46 ± 17.94 27.25 ± 15.83 1.00E:04
C: peptide 3.14 ± 2.19 2.49 ± 1.29 5.05 ± 2.86 0.2
urine total protein 14.10 ± 15.21 26.53 ± 22.48 207.18 ± 154.30 1.00E:04
HbA1C 5.59 ± 0.51 5.57 ± 0.43 6.62 ± 0.91 0.003
HOMA 1 index (IR) 1.96 ± 1.24 2.36 ± 3.20 6.68 ± 7.02 0.09
Table 3: Results of the blood and urine tests.
N: Normal; IFG: Impaired Fasting Glucose; IGT: Impaired Glucose Tolerance; NODAT: New Onset Diabetes After Transplantation; eGFR: Estimated Glomerular 
Filtration Rate; IR: Insulin Resistance; HOMA: Homeostatic Model Assessment
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20%. In our clinical study, it was found that the recipients basic data 
(recipients age, gender, and the time of the hemodialysis) were not 
significantly different concerning the onset of NODAT, and the 
difference in the BMI was also not significant, although the average 
BMI of patients having NODAT was higher compared to patients 
with normal carbohydrate metabolism [7,20]. The low BMI in 
our recipients should reflect the fact that we keep our patients fit. 
According to the WHO, the number of patients worldwide with 
diabetes mellitus has doubled from 170 million to 340 million over 
the past ten years. In addition, the WHO predicts that diabetes 
mellitus will be the seventh leading cause of death by 2030. The 
insulin resistance of HbA1C was significantly different between 
the normal and diabetes groups. The study proved that the time 
of the hemodialysis did not affect the development of NODAT. 
The diabetogenic effect of glucocorticoids, mainly due to insulin 
resistance, is mediated by both impaired insulin-dependent glucose 
uptake in the peripheral tissues and enhanced gluconeogenesis in 
the kidney. We did not investigate the effect of steroids on NODAT 
because all patients received steroids after kidney transplantation. 
Several clinical studies indicate that Tac is associated with a higher 
risk for IGT and NODAT than CsA [21]. Our study showed that 
in patients taking Tac IS therapy, the incidence of the NODAT was 
16%; however, the incidence of NODAT in CsA immunosuppression 
therapy was 3% (p=0.027). We found that the drug level of Tac had 
significant influence on NODAT (p=0.016). In our clinical study, it 
was shown that the risk of NODAT related to Tac was dose dependent, 
and high trough levels enhanced the risk, in particular during the 
NODAT period. Calcineurin inhibitors are diabetogenic by inducing 
a defect in insulin secretion by interfering with the nuclear factor of 
activated T-cell signaling in pancreatic β-cells. This pathway triggers 
the expression of genes critical for β-cell function, including at least 
six genes mutated in hereditary forms of monogenic diabetes [17]. 
Tac induces a reversible suppression of insulin secretion at the level 
of insulin mRNA transcription, mediated by the binding of the drug 
to FK506 binding protein-12 and a subsequent Tac in the β-cells [19]. 
The high level of Tac binding protein-12 present in pancreatic β-cells 
might explain why Tac more profoundly inhibits insulin secretion 
than CsA. Registry analyses, meta-analyses, and the prospective 
study of Vincenti et al. [22] have shown that the risk of NODAT was 
significantly higher in patients on Tac versus CsA [5,23-25]. Our 
study found that the incidence of NODAT was higher among patients 
who were treated with Tac compared with CsA Maes et al. [25] who 
have reported that the number of Tac trough levels >15 ng/mL during 
the first month determined the development of NODAT.
Although CsA therapy allows a reduction in steroid dosages 
with the subsequent reduction of NODAT incidence, Calcineurin 
inhibitors also have been associated with glucose metabolism 
impairment [1,7,19,22]. Several clinical studies indicate that Tac is 
associated with a higher risk for IGT and NODAT than CsA. The 
United States Renal Data System (USRDS) shows that the risk for 
NODAT is 53% higher in patients who receive Tac, and the rate of 
NODAT diagnosis during the second year is also higher [23,26]. 
Retrospective studies and randomized, controlled trials have found 
that the incidence of NODAT is higher among patients who are 
treated with Tac compared with CsA [3-6,19,22]. The appearance of 
a first Tac level >20 ng/mL was associated with a NODAT RR of 9.33 
(95% CI 2.28 to 38.03; p=0.001) after adjusting for age. Nearly 81% of 
patients with NODAT showed a first level >20 ng/mL, whereas only 
22% of patients without NODAT had such a high first level. After this 
point, we did not find any difference in the levels between patients 
with and without NODAT. By contrast, patients with NODAT 
maintained higher concentration-dosage ratios for 6 months, which 
can be explained by the differences in the drug metabolism [27].
The progressive reduction in Calcineurin inhibitor target 
levels has led to a lower incidence of NODAT [6,19,22,27]. Tac 
concentrations of ≤10 ng/mL are associated with both a maximal 
benefit on graft survival and a minimal risk for NODAT [20]. This 
finding is in accordance with several studies that have analyzed the 
glucose metabolism by glucose tolerance tests. After the initiation 
of Tac therapy, there was a 39% reduction in the insulin sensitivity 
index. This index was inversely correlated with the Tac trough level. 
No patients with Tac trough levels <15 ng/mL showed an abnormal 
index. A 33% Tac level reduction resulted in a 36% improvement in 
pancreatic β cell secretion capacity [20]. Because glucose metabolism 
depends more on Tac area under the curve and trough level than 
on peak level, it seems that the change to the new modified release 
formulation of Tac (MR4) will not alter the current knowledge about 
the NODAT-Tac relationship [21].
Tac is associated with a higher rate of NODAT but not with a 
reduced risk for graft failure [2,6,19]. According to Webster et al. 
[25], treating 100 recipients with Tac instead of CsA for the first year 
after transplantation has prevented 12 patients from having acute 
rejection and two from losing their graft but has made an extra five 
patients develop insulin-dependent diabetes. In regard to the function 
of the allograft, we found that there was significant difference in the 
serum creatinine (p=0.001) and eGFR levels (p=0.0001). NODAT 
leads to the deterioration of renal function and urinary proteinuria 
(p=0.0001). In the NODAT group, it seems more reasonable to 
convert to a Calcineurin inhibitor-free regimen to improve glucose 
metabolism, although there is some risk to have an acute rejection 
episode or to reduce Tac dosages [16]. A reduction in blood levels 
of Calcineurin inhibitor may help diminish the risk for NODAT. 
If it is clear that lifestyle modification alone will be insufficient 
to control hyperglycemia, pharmacotherapy targeting glucose 
metabolism should be initiated. In the very early post-transplant 
phase, when corticosteroids are being rapidly tapered, additional 
pharmacotherapy may not be required if the hyperglycemia is mild. 
The choice between insulin and oral hypoglycemic agents depends 
on the severity, timing, and expected duration of hyperglycemia [28]. 
Insulin therapy is safe, particularly when the graft function is not yet 
established or is unstable. Since corticosteroids and Tac are typically 
administered in the morning in patients with kidney transplantation, 
a combination of intermediate and short-acting insulin administered 
several times during the day and corresponding to mealtimes may be 
required [29]. In less urgent instances, oral hypoglycemic agents can 
be commenced without resorting to insulin first-hand.
Our study was limited by the fact that patients came from various 
counties; therefore, we did not set up and change any antidiabetic 
therapies. We would like to look at these patient groups further 
and evaluate the severity of the effects of diabetes on the eyes and 
peripheral nervous system.
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